White Paper

Novel LipoAvail® Liposomal NMN Elevates 6X NAD+

Overview

Liposomal technology encapsulates active ingredients within liposomes, mimicking intestinal cell membranes for improved absorption and bioavailability.

LipoAvail® NMN, Uthever® NMN powered by LipoAvail® Liposomal Technology, offers the only lab-validated liposomal NMN on the market. After 14 consecutive days, the LipoAvail® NMN group demonstrated 1.74 times higher NAD+ levels in mouse liver tissue and 5.95 times higher NAD+ levels in mouse skeletal muscle compared to the regular NMN group.

Download the Liposome White Paper and catalog for more liposomal product like liposomal VC and glutathione.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Latest Content

NMN supplementation proved to mitigate radiotherapy-induced damages

Paid for by Effepharm Ltd

Scientific study validates NMN’s efficacy in alleviating intestinal damages caused by radiotherapy through reducing alterations to gut bacteria composition and function.

NMN New Clinical Finding: Obvious NAD(H) Level Increase

Paid for by Effepharm Ltd

With 7.3% CAGR, The "Nicotinamide Mononucleotide (NMN) Market" size is expected to grow from 194.2 million USD In 2020, to reach 296.5 Million USD by 2026.”